BCOR-CCNB3 fusion–positive sarcoma treated with chemotherapy and carbon-ion radiotherapy: a case report of long-term disease control of a cervical spine case with a 12-year follow-up - Takeaways - MDSpire

BCOR-CCNB3 fusion–positive sarcoma treated with chemotherapy and carbon-ion radiotherapy: a case report of long-term disease control of a cervical spine case with a 12-year follow-up

  • By

  • Naoki Oike

  • Reiko Imai

  • Akira Ogose

  • Takashi Ariizumi

  • Yudai Murayama

  • Tomohiro Miyazaki

  • Kazunaga Kimura

  • Hajime Umezu

  • Hiroyuki Kawashima

  • June 10, 2026

  • 0 min

Share

  • 1

    BCOR–CCNB3 fusion-positive sarcoma (BCS) is a rare subtype of undifferentiated round-cell sarcoma primarily affecting children and adolescents.

  • 2

    The patient, a 14-year-old boy, was treated with systemic chemotherapy and carbon-ion radiotherapy (CIRT), achieving long-term disease control.

  • 3

    CIRT delivered a total dose of 70.4 Gy in 16 fractions, resulting in no evidence of residual tumor after treatment completion.

  • 4

    More than 12 years post-treatment, the patient remains asymptomatic without neurological deficits, local recurrence, or distant metastasis.

  • 5

    This case is the first reported instance of BCS treated with CIRT, suggesting it may be a promising option for challenging cases.

Original Source(s)

BCOR-CCNB3 fusion–positive sarcoma treated with chemotherapy and carbon-ion radiotherapy: a case report of long-term disease control of a cervical spine case with a 12-year follow-up

  • by Naoki Oike, Reiko Imai, Akira Ogose, Takashi Ariizumi, Yudai Murayama, Tomohiro Miyazaki, Kazunaga Kimura, Hajime Umezu, Hiroyuki Kawashima

  • June 10, 2026

Related Content

Development and validation of an interpretable machine learning model for predicting 5-year recurrence in breast cancer

Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma

Understanding the immune microenvironment of ovarian cancer